Nobis Nobis Cartel windows 7 home premium activation key
Yearly Archives: 2007

UPENN Clinical Trial

A Study to Evaluate the Intra-rater and Inter-rater reliability of the Pemphigus Disease Area Index (PDAI) and the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) for Use by Dermatologists To download and print the Informed Consent Form, click HERE. (You will

Posted in Clinical Trials

The use of KC706 for the Treatment of Pemphigus Vulgaris

The purpose of this trial is to (a) determine the ability of KC706 to prevent the appearance of new blisters and heal existing blisters, while maintaining stable doses of corticosteroids and/or immunosuppressants, in patients with pemphigus vulgaris (b) to determine

Posted in Clinical Trials

NYU: Is IVIg Effectiveness Improved by the Concurrent Administration of Cyclophosphamide

The purpose of the trial is to determine whether the effectiveness of IVIg is improved by the concurrent administration of cyclophosphamide. There is evidence that it can, but a formal randomized trial is required to be sure.

Posted in Clinical Trials

Regulatory T Cells Are Severely Reduced in PV

This new study, published in the journal "Dermatology", shows that a severe reduction of T (Treg) cells may be involved in the pathogenesis of pemphigus vulgaris (PV), an autoimmune blistering disease.

Posted in Medical

Loss of Control: Your Choice

No one asks to be “chosen” for chronic illness and/or pain. There are, however, choices you can make which can either empower you or allow you to be a victim of circumstances. Not feeling you are in total control does not

Posted in Health and Lifestyle

Rituximab: A New Treatment for Recalcitrant PV?

Rituximab (RTX) is anti-CD20 chimeric antibody that selectively targets B cells.  CD20 is a molecule that functions as an antigen for it.  CD20 is expressed on mature antibody producing B cells, but not on plasma cells.(1) The FDA has approved

Posted in Medical

Anti-TNF Therapy for Mucous Membrane Pemphigoid

Mucous Membrane Pemphigoid, also known as Cicatricial Pemphigoid, is a serious autoimmune blistering disorder that can result in blindness and other complications as the result of scarring of the mucous membranes.  To our knowledge, there have been 2 reported uses

Posted in Medical

Stanford: Etanercept (Enbrel) to Treat Pemphigus Vulgaris

The primary endpoint is to determine the number of days it takes to achieve a 50% reduction in blister count, and secondary endpoints include a reduction of baseline prednisone dose once the primary endpoint has been achieved. The trial will

Posted in Clinical Trials

Duke Univ: Rituximab for the Treatment of Bullous Pemphigoid

The purpose of this trial is to determine the safety of rituximab for the treatment of bullous pemphigoid.  Secondary clinical endpoints include the number of days to cessation of new blister formation, the ability to reduce prednisone to 25% of

Posted in Clinical Trials

Harbor-UCLA: Effects of Topical Cortiocosteroids on PV Skin Strength

To see if topical (applied to the skin) corticosteroid strengthens the skin of patients with Pemphigus vulgaris, thereby preventing blisters from forming.  The topical corticosteroid to be used in this study is called Clobetasol.  Clobetasol has been approved by the

Posted in Clinical Trials

JOIN TODAY!

The P/P Registry has been approved by the Western Institutional Review Board (WIRB) and is actively enrolling participants.

ENGLISH VERSION